Avalo Therapeutics to Participate in The Citizens Life Sciences Conference
Avalo Therapeutics, a clinical stage biotech company specializing in immune dysregulation treatments, has announced its upcoming participation in the Citizens Life Sciences Conference.
The company's CEO, Dr. Garry Neil, is scheduled to present at the conference on Thursday, May 8, 2025, at 3:00 pm ET in New York. The presentation will be accessible through live webcasts and replays from the company's website.
Investors and interested parties can access the presentation through:
- The "News / Events" section of Avalo's investor relations website at ir.avalotx.com
- Archived webcast replays available for a minimum of 30 days
Avalo Therapeutics, un'azienda biotecnologica in fase clinica specializzata in trattamenti per la disfunzione immunitaria, ha annunciato la sua prossima partecipazione alla Citizens Life Sciences Conference.
Il CEO dell'azienda, Dr. Garry Neil, presenterà alla conferenza giovedì 8 maggio 2025 alle 15:00 ET a New York. La presentazione sarà disponibile tramite webcast in diretta e repliche sul sito web della società.
Investitori e interessati potranno accedere alla presentazione attraverso:
- La sezione "News / Eventi" del sito di relazioni con gli investitori di Avalo all'indirizzo ir.avalotx.com
- Repliche archiviate dei webcast disponibili per almeno 30 giorni
Avalo Therapeutics, una empresa biotecnológica en etapa clínica especializada en tratamientos para la disfunción inmunitaria, ha anunciado su próxima participación en la Citizens Life Sciences Conference.
El CEO de la empresa, Dr. Garry Neil, tiene previsto presentar en la conferencia el jueves 8 de mayo de 2025 a las 3:00 pm ET en Nueva York. La presentación estará disponible mediante transmisiones en vivo y repeticiones desde el sitio web de la empresa.
Los inversores y personas interesadas pueden acceder a la presentación a través de:
- La sección "Noticias / Eventos" del sitio web de relaciones con inversores de Avalo en ir.avalotx.com
- Repeticiones archivadas de la transmisión disponibles por un mínimo de 30 días
Avalo Therapeutics는 면역 조절 치료제를 전문으로 하는 임상 단계 바이오텍 회사로, Citizens Life Sciences Conference에 곧 참여할 예정임을 발표했습니다.
회사의 CEO인 Dr. Garry Neil은 2025년 5월 8일 목요일 오후 3시(동부시간) 뉴욕에서 열리는 컨퍼런스에서 발표할 예정입니다. 발표는 회사 웹사이트를 통해 생중계 및 다시보기로 제공됩니다.
투자자 및 관심 있는 분들은 다음 경로를 통해 발표에 접속할 수 있습니다:
- Avalo 투자자 관계 웹사이트 ir.avalotx.com의 "뉴스 / 이벤트" 섹션
- 최소 30일 동안 보관되는 웹캐스트 다시보기
Avalo Therapeutics, une entreprise biotechnologique en phase clinique spécialisée dans les traitements des troubles immunitaires, a annoncé sa prochaine participation à la Citizens Life Sciences Conference.
Le PDG de la société, Dr. Garry Neil, doit présenter lors de la conférence le jeudi 8 mai 2025 à 15h00 ET à New York. La présentation sera accessible via des webcasts en direct et des rediffusions sur le site internet de la société.
Les investisseurs et les personnes intéressées peuvent accéder à la présentation via :
- La section « Actualités / Événements » du site des relations investisseurs d’Avalo à l’adresse ir.avalotx.com
- Des rediffusions archivées des webcasts disponibles pendant au moins 30 jours
Avalo Therapeutics, ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Behandlungen bei Immunfehlregulation spezialisiert hat, hat seine bevorstehende Teilnahme an der Citizens Life Sciences Conference angekündigt.
Der CEO des Unternehmens, Dr. Garry Neil, wird am Donnerstag, den 8. Mai 2025, um 15:00 Uhr ET in New York auf der Konferenz sprechen. Die Präsentation wird über Live-Webcasts und Wiederholungen auf der Website des Unternehmens zugänglich sein.
Investoren und Interessierte können auf die Präsentation zugreifen über:
- Den Bereich "News / Events" auf der Investor-Relations-Website von Avalo unter ir.avalotx.com
- Archivierte Webcast-Wiederholungen, die mindestens 30 Tage verfügbar sind
- CEO participation in a major life sciences conference indicates continued market visibility and investor outreach efforts
- None.
WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET.
Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. For more information about Avalo, please visit www.avalotx.com.
About AVTX-009
AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.
For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793
or
Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com
FAQ
When is Avalo Therapeutics (AVTX) presenting at the Citizens Life Sciences Conference 2025?
How can I watch Avalo Therapeutics' (AVTX) presentation at the Citizens Life Sciences Conference?
What is the focus area of Avalo Therapeutics (AVTX)?
Who will represent Avalo Therapeutics (AVTX) at the Citizens Life Sciences Conference 2025?
How long will Avalo Therapeutics' (AVTX) conference presentation replay be available?
